Form 10-K/A CS Disco, Inc. For: Dec 31
Exhibit 31.3
CERTIFICATION PURSUANT TO RULES 13a-14(a) UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Kiwi Camara, certify that:
1.I have reviewed this Amendment No. 1 to Annual Report on Form 10-K of CS Disco, Inc.; and
2.Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
Date: April 29, 2022 | By: | /s/ Kiwi Camara | |||||||||
Name: | Kiwi Camara | ||||||||||
Title: | Chief Executive Officer | ||||||||||
(Principal Executive Officer) |
Exhibit 31.4
CERTIFICATION PURSUANT TO RULES 13a-14(a) UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Michael Lafair, certify that:
1.I have reviewed this Amendment No. 1 to Annual Report on Form 10-K of CS Disco, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
Date: April 29, 2022 | By: | /s/ Michael Lafair | |||||||||
Name: | Michael Lafair | ||||||||||
Title: | Chief Financial Officer | ||||||||||
(Principal Financial and Accounting Officer) |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bionxt Solutions Announces Odf Cladribine Update and Financing
- Deveron Announces Closing of Private Placement of Convertible Debentures
- CIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the Firm
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!